Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Wolf-Karsten Hofmann, Arwin Mehralivand, Laurenz Steiner, Nanni Schmitt, Ahmed Jawhar, Cleo-Aron Weis, Stefanie Uhlig, Justine Danner, Vladimir Riabov, Ali Darwich, Qingyu Xu, Julia Obländer, Eva Altrock, Tobias Boch, Nadine Weimer, Florian Nolte, Antje Knaflic, Mohamad Jawhar, Alexander Streuer, Verena Haselmann, Daniel Nowak, Johann-Christoph Jann, Verena Nowak, Alexander Marx, Georgia Metzgeroth, Johanna Flach, Iris Palme
Publikováno v:
Leukemia
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model
Autor:
Samuele Massarut, Ingrid Potyka, Christobel Saunders, Gloria Petralia, Marcelle Bernstein, Norman R. Williams, Steinar Lundgren, Konstantin J. Dedes, Tammy Corica, Magali Le Blanc-Onfroy, Mary Falzon, Frederik Wenz, W. Eiermann, Fernando Bozza, David Joseph, Marc Sütterlin, Dennis R. Holmes, Montserrat Pazos, Nicholas Roberts, Jayant S. Vaidya, Michael Alvarado, Chris Brew-Graves, Jeffrey S Tobias, Elena Sperk, Douglas Brown, Max Bulsara, David McReady, Steffi Pigorsch, Jens Uwe Blohmer, Michael Baum, Richard A. Hoefer, Günther Gruber, Lorenzo Vinante, Michael Douek, Henrik Flyger, Marcus Niewald, Siobhan Laws, Pond R. Kelemen, Wojciech Polkowski
Publikováno v:
British Journal of Cancer
Background The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyse
Autor:
Pierre Zachee, David M. Ross, Lynda Foltz, Atanas Radinoff, Francesco Mannelli, Evren Zor, Francisco Cervantes, Francesco Passamonti, Heinz Gisslinger, Geralyn Gilotti, Haifa Kathrin Al-Ali, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Islam Sadek, Ranjan Tiwari, Norio Komatsu
Publikováno v:
Leukemia
Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with
Autor:
Abdolreza Haghpanah, Anahita Dehghani, Mehdi Salehipour, Alireza Hosseinpour, Fatemeh Masjedi, Jamshid Roozbeh
Publikováno v:
Prostate Cancer and Prostatic Diseases
Background To explore the potential mechanisms of SARS-CoV-2 in targeting the prostate gland, leading to exacerbation of benign prostatic hyperplasia (BPH) symptoms and greater risks of BPH complications such as acute urinary retention. Methods A cat
Autor:
Vincent Cheung, Rosalin Cooper, Isar Nassiri, Anna Olsson-Brown, Robert A. Watson, Mark Coles, Umair Akbani, Mark R. Middleton, Chelsea A Taylor, Joseph J. Sacco, Weiyu Ye, Oliver Brain, Rubeta N Matin, Robert D Morgan, Miranda Payne, Benjamin P. Fairfax, Nicholas Coupe
Publikováno v:
British Journal of Cancer
BRITISH JOURNAL OF CANCER
BRITISH JOURNAL OF CANCER
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods Retrospecti
Autor:
Martina Pontone, Fabrizio Ensoli, Enea Gino Di Domenico, Elena Papa, Atelda Romano, Valentina Laquintana, Caterina Viggiani, Livia Ronchetti, Ornella Di Bella, Aldo Morrone, Gennaro Ciliberto, Paolo Falcucci, Daniela Renzi, Svitlana Gumenyuk, Iole Cordone, Simona di Martino, Laura Conti, Francesca Palombi, Diana Giannarelli, Branka Vujovic, Andrea Mengarelli, Francesco Pisani, Antonia La Malfa, Francesco Marchesi, Chiara Mandoj, Fulvia Pimpinelli
Publikováno v:
Leukemia
Autor:
Anthony Howell, Raj B. Patel, Ivana Sestak, Robert E. Coleman, Glen M. Blake, Richard Eastell, Jack Cuzick
Publikováno v:
British Journal of Cancer
Sestak, I, Blake, G, Patel, R, Cuzick, J, Howell, A, Coleman, R & Eastell, R 2021, ' Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years : 7-year results from the IBIS-II prevention trial ', British Journal of Cancer, vol. 124, no. 8, pp. 1373-1378 . https://doi.org/10.1038/s41416-020-01228-2
Sestak, I, Blake, G, Patel, R, Cuzick, J, Howell, A, Coleman, R & Eastell, R 2021, ' Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years : 7-year results from the IBIS-II prevention trial ', British Journal of Cancer, vol. 124, no. 8, pp. 1373-1378 . https://doi.org/10.1038/s41416-020-01228-2
Background Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. Methods One thousand four hundred and ten women were included in a BMD substudy and stratified into three strata accordin
Autor:
Ying Jing, Yi Zhang, Minhua Yu, Mei-Chun Cai, Lin Cheng, Wenjing Wang, Xia Yin, Huaiwu Lu, Lihua Qiu, Caiyan Zhang, Haijiao Lu, Wen Di, Li Tan, Jie Wu, Jiejun Cheng, Guanglei Zhuang, Weihua Lou
Publikováno v:
British Journal of Cancer
Background We aimed to comprehensively evaluate the immunologic landscape at baseline and upon chemotherapy in cervical cancer. The information should aid ongoing clinical investigations of checkpoint blockade immunotherapies in this disease setting.
Autor:
Debu Tripathy, Gregory N. Fuller, Chao Gao, Kenneth R. Hess, Sami I. Bashour, Donald F. Schomer, Nuhad K. Ibrahim
Publikováno v:
British Journal of Cancer
BackgroundCNS miliary metastasis (MiM) is poorly recognised in breast and other malignancies. Given its rarity, little epidemiologic, radiographic and clinical data are known. Although usually identified on neuroimaging, criteria for radiographic dia
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang